Deep brain stimulation (DBS) is commonly known as "brain pacemaker". It can emit electrical pulses to the relevant neural nuclei that controls movement through clicks implanted into the brain, and regulates abnormal neural electrical activity. It is a conventional treatment method for Parkinson's disease , primary tremor and dystonia, and drug-induced refractory epilepsy.
On October 10, according to Medtronic, its world's first deep brain nerve stimulator with perception technology was approved by National Medical Administration !
Medtronic's Percept™ PC system is a device similar to pacemaker that can be implanted under the skin of the patient's trunk, and its wires are connected to the brain area associated with a specific nervous system disease.
The difference between this device and other deep brain stimulation systems is that in addition to providing nerve stimulation therapy to treat Parkinson's disease, epilepsy, obsessive-compulsive disorder and other diseases, it can also continuously capture and record brain signals, and can transmit the captured EEG signals to the doctor through in-site communication, and can be compatible with 1.5T and 3.0T magnetic resonance scans when on-the-go. This is the first deep brain nerve stimulator in the world that can capture and record local field potential signals.
According to public information, Medtronic's Percept™ PC system began to be launched in Europe in early 2020 and was approved by the US FDA in June 2020. The birth of the Percept™ PC system with perceptible functions also marks that DBS has entered the digital age , greatly promoting the effect of DBS treatment.
DBS technology has received widespread attention
platform land
In recent years, deep brain stimulation technology (DBS) has received more and more widespread attention, and has been widely used in clinical practice for motor disorders caused by diseases such as Parkinson. At the same time, it has great potential in central nervous system diseases such as anxiety, depression, refractory epilepsy , and refractory obsessive-compulsive disorder.
At present, more than 180,000 patients worldwide have undergone DBS implantation. Research shows that DBS has achieved remarkable results in controlling the motor symptoms of Parkinson's disease and reducing drug intake.
According to public data, there are more than 3 million Parkinson's disease patients in my country, and will reach 5 million by 2030; in addition, there are more than 10 million patients with Alzheimer's disease and nearly 10 million patients with epilepsy, and there are huge demand for DBS treatment.
At present, DBS technology has begun to expand its application to other neuropsychiatric diseases, such as major depression and Alzheimer's disease. As DBS research continues to advance, the application space for DBS therapy will be unlimited in the future.
Heyihui Medical Views
Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), and Vaginal Neurological Stimulation (VNS) are the top three segments of neuromodulation. Currently, this market is occupied by three giants Medtronic, Abbott , and Boston Science .
According to the information of Equipment Home, the global production of neurostimulators in 2018 was about 189,900 units, with sales of about US$4 billion, while the market output of Chinese neurostimulators accounts for only about 1.63% of the world. At present, Jingyu Medical (dual target deep brain electrical stimulation technology) and Pinchi Medical (Pinchi series brain pacemakers) have been included in the field of domestic neuroregulatory devices.
With Medtronic's Percept™ PC approved in China, what changes will the domestic market usher in? Worth paying attention.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-